Kiniksa Pharmaceuticals (KNSA.US) was covered for the first time by Wells Fargo, giving it an increase rating, with a target price of $34.00.
Kiniksa Pharmaceuticals Analyst Ratings
Wells Fargo Initiates Coverage On Kiniksa Pharmaceuticals With Overweight Rating, Announces Price Target of $34
Komo: Maintaining the Kiniksa Pharmaceuticals (KNSA.US) rating, adjusted from an increase in holdings to an increase rating, and the target price was adjusted from $26.00 to $30.00.
Kiniksa Pharmaceuticals Analyst Ratings
JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $30
Kiniksa Pharmaceuticals Analyst Ratings
Evercore ISI Group: Maintaining the Kiniksa Pharmaceuticals (KNSA.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $25.00 to $30.00.
Evercore ISI Group Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $30
Buy Rating Affirmed for Kiniksa Pharmaceuticals Amid Strong Q1 Performance and Promising Drug Prospects
Buy Rating Affirmed for Kiniksa Pharmaceuticals Amidst Growth Potential and Strong Commercial Execution
Kiniksa Pharmaceuticals (KNSA) Receives a Buy From Goldman Sachs
Analysts Are Bullish on These Healthcare Stocks: G1 Therapeutics (GTHX), Kiniksa Pharmaceuticals (KNSA)
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Rhythm Pharmaceuticals (RYTM) and Kiniksa Pharmaceuticals (KNSA)
Strong Arcalyst Sales and Promising Pipeline Reinforce Kiniksa Pharmaceuticals Buy Rating
Kiniksa Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Kiniksa Pharmaceuticals (KNSA) and UnitedHealth (UNH)
Promising Growth and Strategic Investments Bolster Buy Rating for Kiniksa Pharmaceuticals
J.P. Morgan Sticks to Its Buy Rating for Kiniksa Pharmaceuticals (KNSA)
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $32